InvestorsHub Logo
Followers 14
Posts 2297
Boards Moderated 0
Alias Born 12/20/2012

Re: top123 post# 219331

Wednesday, 02/28/2018 6:54:56 PM

Wednesday, February 28, 2018 6:54:56 PM

Post# of 402945
My recolection is the same as yours. I was also looking for "leader".

Found it, 1/29/18 pr:"After a recent successful Phase 2 trial in Oral Mucositis (OM), the Company believes that it is the clear global leader in this area as it develops an easy-to-administer oral rinse medicine for the prevention of severe Oral Mucositis (SOM) in Head and Neck Cancer (HNC) patients receiving chemoradiation—analysts estimate this market could reach $1 billion in coming years."

http://www.ipharminc.com/press-release/2018/1/29/innovation-pharmaceuticals-brilacidin-franchise-anchored-in-three-clinical-indications-oral-mucositis-inflammatory-bowel-disease-and-serious-skin-infections-expands-into-dermatologic-diseases

Those are words of confidence, considering he has to be aware of Galera's recent 2b results(they share a common scientific advisor, Dr. Stephen Sonis).
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News